Bayer invests heavily in oncology, neurology, and women's health, driving innovation through advanced biopharma technologies.
Takeda leads in rare diseases and immunology, supported by AI, CRISPR, and advanced manufacturing.
GSK emphasizes respiratory health, vaccines, and oncology, leveraging NGS, AI, and mRNA platforms.
Roche targets oncology, biosimilars, and diabetes, focusing on sequencing, bioprocessing, and AI.
%20(1).gif)
